These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 36228963)
1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Geyer CE; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G; Armstrong AC; Arnedos M; Balmaña J; Bergh J; Bliss J; Delaloge S; Domchek SM; Eisen A; Elsafy F; Fein LE; Fielding A; Ford JM; Friedman S; Gelmon KA; Gianni L; Gnant M; Hollingsworth SJ; Im SA; Jager A; Jóhannsson ÓÞ; Lakhani SR; Janni W; Linderholm B; Liu TW; Loman N; Korde L; Loibl S; Lucas PC; Marmé F; Martinez de Dueñas E; McConnell R; Phillips KA; Piccart M; Rossi G; Schmutzler R; Senkus E; Shao Z; Sharma P; Singer CF; Španić T; Stickeler E; Toi M; Traina TA; Viale G; Zoppoli G; Park YH; Yerushalmi R; Yang H; Pang D; Jung KH; Mailliez A; Fan Z; Tennevet I; Zhang J; Nagy T; Sonke GS; Sun Q; Parton M; Colleoni MA; Schmidt M; Brufsky AM; Razaq W; Kaufman B; Cameron D; Campbell C; Tutt ANJ; Ann Oncol; 2022 Dec; 33(12):1250-1268. PubMed ID: 36228963 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Yamauchi H; Toi M; Takayama S; Nakamura S; Takano T; Cui K; Campbell C; De Vos L; Geyer C; Tutt A Breast Cancer; 2023 Jul; 30(4):596-605. PubMed ID: 37005966 [TBL] [Abstract][Full Text] [Related]
4. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations. Zettler CM; De Silva DL; Blinder VS; Robson ME; Elkin EB JAMA Netw Open; 2024 Jan; 7(1):e2350067. PubMed ID: 38170520 [TBL] [Abstract][Full Text] [Related]
6. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661 [TBL] [Abstract][Full Text] [Related]
7. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071 [TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Ganz PA; Bandos H; Španić T; Friedman S; Müller V; Kuemmel S; Delaloge S; Brain E; Toi M; Yamauchi H; de Dueñas EM; Armstrong A; Im SA; Song CG; Zheng H; Sarosiek T; Sharma P; Geng C; Fu P; Rhiem K; Frauchiger-Heuer H; Wimberger P; t'Kint de Roodenbeke D; Liao N; Goodwin A; Chakiba-Brugère C; Friedlander M; Lee KS; Giacchetti S; Takano T; Henao-Carrasco F; Virani S; Valdes-Albini F; Domchek SM; Bane C; McCarron EC; Mita M; Rossi G; Rastogi P; Fielding A; Gelber RD; Scheepers ED; Cameron D; Garber J; Geyer CE; Tutt ANJ J Clin Oncol; 2024 Apr; 42(11):1288-1300. PubMed ID: 38301187 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Piccart M; Procter M; Fumagalli D; de Azambuja E; Clark E; Ewer MS; Restuccia E; Jerusalem G; Dent S; Reaby L; Bonnefoi H; Krop I; Liu TW; Pieńkowski T; Toi M; Wilcken N; Andersson M; Im YH; Tseng LM; Lueck HJ; Colleoni M; Monturus E; Sicoe M; Guillaume S; Bines J; Gelber RD; Viale G; Thomssen C; J Clin Oncol; 2021 May; 39(13):1448-1457. PubMed ID: 33539215 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies. Morganti S; Bychkovsky BL; Poorvu PD; Garrido-Castro AC; Weiss A; Block CC; Partridge AH; Curigliano G; Tung NM; Lin NU; Garber JE; Tolaney SM; Lynce F Oncologist; 2023 Jul; 28(7):565-574. PubMed ID: 37210568 [TBL] [Abstract][Full Text] [Related]
11. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Robson ME; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Tung N; Armstrong A; Dymond M; Fielding A; Allen A; Conte P Eur J Cancer; 2023 May; 184():39-47. PubMed ID: 36893711 [TBL] [Abstract][Full Text] [Related]
12. Maintenance Olaparib for Germline Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963 [TBL] [Abstract][Full Text] [Related]
13. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M; Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970 [TBL] [Abstract][Full Text] [Related]
14. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902 [TBL] [Abstract][Full Text] [Related]
15. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P; Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483 [TBL] [Abstract][Full Text] [Related]
16. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051 [TBL] [Abstract][Full Text] [Related]
17. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601 [TBL] [Abstract][Full Text] [Related]
18. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Kindler HL; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; Bordia S; McGuinness D; Cui K; Locker GY; Golan T J Clin Oncol; 2022 Dec; 40(34):3929-3939. PubMed ID: 35834777 [TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J; Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573 [TBL] [Abstract][Full Text] [Related]
20. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]